Zimmer Biomet’s (ZBH) Buy Rating Reaffirmed at Argus

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating restated by investment analysts at Argus in a research report issued on Thursday, Benzinga reports. They currently have a $125.00 target price on the medical equipment provider’s stock. Argus‘s price target points to a potential upside of 26.92% from the company’s current price.

A number of other research firms have also recently commented on ZBH. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Canaccord Genuity Group boosted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a report on Monday, August 10th. Sanford C. Bernstein boosted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Barclays raised Zimmer Biomet to a “hold” rating in a report on Wednesday, October 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Seven research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $104.47.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH traded up $3.63 during trading hours on Thursday, reaching $98.49. 807,042 shares of the stock were exchanged, compared to its average volume of 2,225,187. The firm has a market capitalization of $18.79 billion, a price-to-earnings ratio of 23.97, a P/E/G ratio of 1.81 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $104.15. The stock’s fifty day simple moving average is $95.18 and its 200 day simple moving average is $91.41.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the company earned $2.07 earnings per share. The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts predict that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Activity at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by company insiders.

Institutional Trading of Zimmer Biomet

Large investors have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp bought a new stake in shares of Zimmer Biomet in the 2nd quarter valued at approximately $922,000. Hsbc Holdings PLC bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $35,417,000. Legal & General Group Plc bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $126,167,000. Rakuten Investment Management Inc. bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $2,945,000. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at approximately $3,753,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.